Gossamer Bio, Inc. (GOSS)
10.71
-0.22
(-2.01%)
USD |
NASDAQ |
Oct 02, 16:00
10.72
+0.01
(+0.09%)
After-Hours: 20:00
Gossamer Bio Gross Profit Margin (Quarterly) : 97.27% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 97.27% |
| March 31, 2026 | 98.63% |
| December 31, 2025 | 98.36% |
| September 30, 2025 | 98.35% |
| June 30, 2025 | 98.15% |
| Date | Value |
|---|---|
| March 31, 2025 | 96.54% |
| December 31, 2024 | 88.54% |
| September 30, 2024 | 88.59% |
| June 30, 2024 | 98.96% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| United Therapeutics Corp. | 87.30% |
| Arbutus Biopharma Corp. | 98.92% |
| Kura Oncology, Inc. | 97.07% |
| ACADIA Pharmaceuticals, Inc. | 90.81% |
| Alnylam Pharmaceuticals, Inc. | 76.88% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Assets | -75.64% |
| Return on Invested Capital | -181.5% |
| Operating Margin (Quarterly) | -282.2% |
| Return on Net Operating Assets | -958.1% |